



A34694-A-PCT-USA-A 070050.-2544
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fisher, et al.
Serial No. : 10/795,927
Filed : March 8, 2004
For ANTI-TUMOR EFFECTS OF PROSTATE CARCINOMA TUMOR
ANTIGEN-1

REQUEST FOR A CORRECTED FILING RECEIPT

I hereby certify that this paper is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450, Attention: Office of Initial Patent Examination's
Customer Service Center

November 17, 2004

Date of Deposit

Lisa B. Kole

Attorney Name



Signature

35,225

Registration No.

November 17, 2004

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
MS Office of Initial Patent Examination's
Customer Service Center

Sir:

Under "Title", ANTI-TUMOR EFFECTS OF PROSTAGE
CARCINOMA TUMOR ANTIGEN-1, please correct to read, ANTI-TUMOR EFFECTS
OF PROSTATE CARCINOMA TUMOR ANTIGEN-1. The correct information is
written in red ink on the attached copy of the Filing Receipt.

Applicant hereby respectfully requests the issuance of a corrected Filing Receipt.

Applicant does not believe that any fee is required in connection with the submission of this document. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. Duplicate copies of this sheet are enclosed.

Respectfully submitted,

BAKER BOTTS LLP


By: 

Lisa B. Kole

Patent Office Reg. No. 35,225

30 Rockefeller Plaza
New York, NY 10012-4498

Attorney for Applicant
212-408-2628



UNITED STATES PATENT AND TRADEMARK OFFICE


UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/795,927	03/08/2004	1614	493	A34694-PCT-USA-A 070050.2	18	11	4

CONFIRMATION NO. 2669

21003
 BAKER & BOTTS
 30 ROCKEFELLER PLAZA
 NEW YORK, NY 10112

UPDATED FILING RECEIPT



OC000000013573280

Date Mailed: 08/18/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Paul B. Fisher, Scarsdale, NY;
 Rahul V. Gopalkrishnan, New York, NY;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/US02/28587 09/06/2002
 which is a CIP of 09/948,227 09/07/2001

Foreign Applications

If Required, Foreign Filing License Granted: 04/23/2004

Projected Publication Date: 11/25/2004

Non-Publication Request: No

Early Publication Request: No

**** SMALL ENTITY ******Title**

Anti-tumor effects of prostate Carcinoma Tumor Antigen-1
 prostate

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

BEST AVAILABLE COPY